摘要
目的:通过对2011-2013年恺德心血管病医院调脂药物临床用药情况分析,结合最新研究报告、作用机制以及不良反应,概述调脂药的用药情况以及用药趋势,为临床合理用药提供参考。方法:回顾性分析2011-2013年恺德心血管病医院调脂药的临床用药情况,以调脂药的销售金额、用药频率(DDDs)、构成比例排序法进行统计分析。结果:2011-2013年阿托伐他汀(阿乐+立普妥)使用金额居调脂药物的首位,并且逐年显著增加,DDDs比例均在85%以上。2013年新引进的瑞舒伐他汀DDDs占11.98%,而苯扎贝特的DDDs逐年下降。结论:恺德心血管病医院调脂药的使用情况基本符合目前临床治疗趋势,但也存在临床上对调脂药认识不足和使用不合理的现象。应深入了解各种调脂药的调脂机制,根据患者的个体情况,合理选用或联用调脂药。
Objective： We analyzed the medication of lipid regulating agents from 2011 to 2013 combining with the mechanism, adverse reaction and latest research, and provide some reference for clinical drug uses. Methods： Retrospectively statistical analyzing the data from 2011 to 2013 with the sequencing method of the sales amount, Defined Daily Dose System （DDDs） and composition ratio. Results： In the past two years, Atorvastatin has been the first in sales amount, and will be increasing year by year. Its DDDs also were more than 85% of all the lipid regulating agents.The promising new one-Rosuvastatin was introduced in 2013 with the DDDs 11.98%.However, the DDDs of Bezafibrate was decreasing. Conclusion： The medication of lipid regulating agents in our hospital was basically in line with current cilinical tendency. However the lack of awareness and unreasonable use of lipid regulating agents should be payed more attention to. It is best to have a thorough understanding of the mechanism of lipid regulating agents, select and use them rationally according to the patients＇ disease.
出处
《中国药事》
CAS
2015年第2期215-219,共5页
Chinese Pharmaceutical Affairs
关键词
调脂药
高血脂
销售金额
用药频度
临床合理用药
lipid regulating agents
hyperlipemia
sales amount
Defined Daily Dose System （DDDs）
clinicalrational drug use
